Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
暂无分享,去创建一个
K. Harrington | M. Monga | E. Vokes | R. Ferris | J. Shaw | V. Grünwald | A. Colevas | S. Kasper | F. Worden | L. Licitra | R. Haddad | M. Gillison | N. Saba | K. Cocks | M. Derosa | J. Fayette | M. Lynch | G. Blumenschein | M. Tahara | N. Kiyota | J. Guigay | L. Morrissey | C. Even | F. Taylor | Dimitrios Colevas